ERWINAZE: payments to doctors
Payments that named ERWINAZE as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $103K
- Providers
- 77
- Transactions
- 87
- Average per transaction
- $1,184
The per-transaction average — $1,184 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 77 providers the average total is $1,337, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Jazz Pharmaceuticals Inc. | $87,666 | 85.1% |
| JAZZ Pharmaceuticals Inc. | $15,317 | 14.9% |